Pfizer company headlines, earnings, strategy, leadership, and market-moving business updates.
Market data may be delayed. For informational purposes only. Not investment advice.
Investors reacted negatively after Pfizer said its lung cancer therapy, sigvotatug vedotin, did not significantly improve survival in a late-stage study, sending the stock lower on the day.
THE APEX TIMES
THE APEX TIMES
A recent market-oriented article highlights how dividend payments from large healthcare companies can be translated into a simple annual cash-flow estimate for shareholders, using Pfizer and Johnson & Johnson as examples.
THE APEX TIMES
Pfizer announced that Chief Financial Officer Dave Denton plans to leave the role effective August 15, citing a new professional opportunity.
THE APEX TIMES
A new pan-European research push focused on obesity and cardiometabolic disease is set to accelerate early science and help new entrants, according to a report that also points to ongoing competitive momentum around obesity therapeutics involving Pfizer.
THE APEX TIMES
A fresh look at Pfizer’s (PFE) recent financial performance has revived debate over whether the stock is trading below its value, with one market-focused analysis suggesting the shares could be roughly 10% undervalued.
THE APEX TIMES
Investors appeared to weigh Pfizer’s near-term leadership change against the company’s longer-term promise that cost cuts and newer medicines will support its 2026 earnings expectations.
THE APEX TIMES
Pfizer (PFE) closed at $25.22, down 2.72% from the prior session, in a move the latest market commentary linked to changing conditions for investors.
THE APEX TIMES
The drugmaker said it has appointed an interim head of finance following the exit of its chief financial officer, while confirming it expects to meet its full-year guidance.
THE APEX TIMES
Dave Denton will leave Pfizer in August, according to a market report, as the drugmaker works through a post-COVID operating reset.
